

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280

Status	RECRUITING
Phase	Phase 1
Sponsor	Elizabeth C. Verna
Enrollment	8 participants

Key Eligibility Criteria

Inclusion (5)

- Able to provide informed consent
- Age e 18 years old
- Clinical diagnosis of AIH and/or PSC
- Listed for liver transplantation
- Epstein-Barr virus (EBV) seropositive within 12 months of screening

Exclusion (18)

- Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis
- Prior transplant
- Listed for multiorgan transplant
- Acute liver failure
- Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma
- ... and 13 more (see full listing online)

Locations (1 total)

Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States